Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Oramed Pharmaceuticals (NASDAQ:ORMP) from a hold rating to a buy rating in a research note released on Saturday.

Separately, Weiss Ratings upgraded Oramed Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, June 11th. One analyst has rated the stock with a Hold rating, According to data from MarketBeat, the company has a consensus rating of “Hold”.

Oramed Pharmaceuticals Price Performance

Oramed Pharmaceuticals stock opened at $4.48 on Friday. Oramed Pharmaceuticals has a 1 year low of $1.98 and a 1 year high of $5.19. The firm’s 50 day moving average price is $4.18 and its 200-day moving average price is $3.84. The stock has a market cap of $186.37 million, a P/E ratio of 1.09 and a beta of 1.22.

Oramed Pharmaceuticals (NASDAQ:ORMP) last issued its earnings results on Monday, August 10th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.52). As a group, equities analysts expect that Oramed Pharmaceuticals will post 1.24 EPS for the current year.

Insider Transactions at Oramed Pharmaceuticals

In other Oramed Pharmaceuticals news, COO Joshua Hexter sold 137,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $4.46, for a total transaction of $611,020.00. Following the sale, the chief operating officer directly owned 1,023,384 shares in the company, valued at $4,564,292.64. This represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Avraham Gabay sold 73,360 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $4.51, for a total value of $330,853.60. Following the sale, the chief financial officer owned 671,785 shares in the company, valued at approximately $3,029,750.35. This trade represents a 9.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 20.77% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Oramed Pharmaceuticals

Large investors have recently modified their holdings of the stock. Bank of America Corp DE lifted its position in Oramed Pharmaceuticals by 2.7% in the first quarter. Bank of America Corp DE now owns 146,152 shares of the biotechnology company’s stock worth $497,000 after buying an additional 3,909 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Oramed Pharmaceuticals by 5.1% in the first quarter. Dimensional Fund Advisors LP now owns 158,209 shares of the biotechnology company’s stock valued at $538,000 after acquiring an additional 7,738 shares during the period. XTX Topco Ltd raised its stake in shares of Oramed Pharmaceuticals by 59.9% in the fourth quarter. XTX Topco Ltd now owns 38,182 shares of the biotechnology company’s stock valued at $109,000 after acquiring an additional 14,297 shares during the period. Kathmere Capital Management LLC bought a new stake in shares of Oramed Pharmaceuticals in the 1st quarter worth about $51,000. Finally, Jane Street Group LLC boosted its stake in shares of Oramed Pharmaceuticals by 35.3% during the 1st quarter. Jane Street Group LLC now owns 67,173 shares of the biotechnology company’s stock worth $144,000 after purchasing an additional 17,510 shares during the period. Institutional investors own 12.73% of the company’s stock.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.